Twitxy Saved

Danielle Bitterman, MD

@dbittermanmd

Leading AI for Clinical Trials at AstraZeneca | Physician | Previously Harvard Med & Mass General Brigham
Boston, MA bittermanlab.org Joined March 2017
641 Following 1.4K Followers 441 Posts

Latest posts 5

Pinned post

Danielle Bitterman, MD @dbittermanmd
🩺💡The Bitterman lab has spend much of the past year researching #LLMs for healthcare. This post summarizes our inroads into making LLMs safer and reliable for clinicians and patients: huggingface.co/blog/shanchen/….

We'll be at #EMNLP2024 - come chat if you have similar interests!
huggingface.co What We Learned About LLM/VLMs in Healthcare AI Evaluation: A Blog post by Shan Chen on Hugging Face
3 replies 14 reposts 82 likes 8.4K views View on X
Danielle Bitterman, MD @dbittermanmd
Very excited to be joining AZ to tackle the critical question in AI for drug development: How can AI speed up, improve success rate, and improve availability of clinical trials without compromising our high safety and evidentiary standards?
Pearl Freier Verified account @PearlF May 18
AstraZeneca recruited physician scientist @dbittermanmd from her research lab within the AI in Medicine Program at Mass General Brigham & Dept of Radiation Oncology at the Brigham 2b VP of AI for Clinical Development. She'll be leading clinical AI across R&D at $AZN. Congrats!
View quoted post on X
15 replies 12 reposts 123 likes 22K views View on X
Danielle Bitterman, MD @dbittermanmd
Thanks for highlighting! The good news is that @shan23chen's recipe that improved LLM safety is accessible for health systems and small academic labs like ours! We used 2 × A100 80GB and can be done in <1hr for our open source model. Estimated < $10 if using cloud GPU renting.
Rohan Paul Verified account @rohanpaul_ai Oct 17, 2025
💊 Not a very good news for Medical LLMs.

A new Mass General Brigham study shows leading LLMs often try to please the user in medical chats, and to do that, can output wrong advice.

Paper shows that default models will confidently echo bad medical assumptions, and that a small behavior nudge plus a 300-example fine-tune can push rejection of harmful requests to 99% to 100% without hurting core knowledge.

They built 50 trick questions that treat a brand drug and its generic as different, then asked 5 models to answer.

GPT-4, GPT-4o, and GPT-4o-mini agreed with the wrong premise 100% of the time, Llama3-8B agreed 94%, and Llama3-70B rejected fewer than 50%.

This behavior is sycophancy, the model goes along with a bad assumption even when it knows the 2 names are the same drug.

Adding a refusal cue and asking the model to recall the brand to generic link first raised rejections to 94% for GPT-4 and GPT-4o, 92% for Llama3-70B, and 62% for GPT-4o-mini.

Small supervised fine-tuning on 300 examples then generalized the skill, giving GPT-4o-mini 100% and Llama3-8B 99% rejection on new cancer drug tests.

The models also explained their rejections correctly in 79% and 70% of those cases, and scores on 10 standard medical benchmarks stayed about the same.

The recipe is simple, allow refusal, cue factual recall before answering, and fine-tune on illogical request pairs so the model spots and blocks false premises.

This work isolates a real failure mode and shows a low-cost way to harden medical chat systems fast.

Health systems should adopt the rejection hint + factual recall + small fine-tune pattern and monitor for regressions as base models change.

---

nature. com/articles/s41746-025-02008-z
View quoted post on X